SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Jun 4, 2007 -- Cytokinetics, Incorporated (NasdaqGM:CYTK - News) announced today that data from clinical trials relating to its oncology program were presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Two of these abstracts relate to Phase II clinical trials evaluating ispinesib that were sponsored by GlaxoSmithKline (GSK) or the National Cancer Institute (NCI). The third abstract relates to a clinical trial sponsored by Cytokinetics evaluating SB-743921.
